Lymphocyte-mediated cytotoxicity in patients with renal and transitional cell carcinoma receiving BCG.
Our modified lymphocyte-mediated microcytotoxicity assay, which allows the serial estimation of lymphocyte cytotoxicity, was used to evaluate the immune response of patients with advanced renal cell and transitional cell carcinoma who were receiving BCG therapy. Preliminary data suggested that this assay may be useful in monitoring cancer patients receiving BCG.
D000230:Adenocarcinoma / Q000276:immunology / Q000628:therapy; D001500:BCG Vaccine / Q000494:pharmacology*; D002295:Carcinoma, Transitional Cell / Q000276:immunology / Q000628:therapy; D003602:Cytotoxicity, Immunologic; D006801:Humans; D007680:Kidney Neoplasms / Q000276:immunology* / Q000628:therapy; D008214:Lymphocytes / Q000276:immunology*; D001749:Urinary Bladder Neoplasms / Q000276:immunology* / Q000628:therapy
D001500:BCG Vaccine